HIV Integrase Inhibitor Pharmacogenetics: An Exploratory Study

Area of Science:

• Pharmacogenomics
• HIV Therapeutics
• Clinical Pharmacology

Background:

• Integrase strand transfer inhibitors (INSTIs) are crucial for HIV treatment.
• Individual variability in side effect occurrence necessitates further investigation.
• Understanding genetic influences can optimize INSTI therapy.

Purpose of the Study:

• To explore associations between single-nucleotide polymorphisms (SNPs) and clinical outcomes in HIV patients on INSTIs.
• To examine the impact of SNPs on drug concentration, adverse events, and treatment efficacy.
• To identify potential pharmacogenetic markers for personalized HIV management.

Main Methods:

• Adult HIV patients on INSTI-based regimens were recruited and genotyped.
• Analysis involved multiple linear or logistic regression with relevant covariates.
• Statistical significance was set at p < 0.05 to detect associations between genetic variants and clinical data.

Main Results:

• A sample of 88 participants, predominantly Caucasian males, was analyzed.
• Abnormal dream occurrence showed a statistically significant difference between regimens (p=0.028).
• Several SNPs were associated with adverse event profiles when INSTI regimens were grouped.

Conclusions:

• Exploratory findings suggest a need for further research into factors affecting HIV patient outcomes.
• Associations between SNPs and adverse events warrant confirmation in larger cohorts.
• Future studies may elucidate pharmacogenetic mechanisms underlying INSTI tolerability and efficacy.